BlackRock, Inc. Reduces Stake in ARS Pharmaceuticals, Inc. to 4.98%

On April 27, 2026, BlackRock, Inc. filed a Schedule 13G/A with the SEC, reporting a decrease in its ownership of ARS Pharmaceuticals, Inc. (SPRY). As of the event date on March 31, 2026, BlackRock beneficially owns 4,946,412 shares of common stock, representing 4.98% of the company's outstanding shares. This filing marks an amendment to a previous position, indicating that BlackRock's stake has fallen below the 5% threshold. Of the total shares held, BlackRock reports sole voting power over 4,860,113 shares and sole dispositive power over the full 4,946,412 shares. The filing clarifies that the securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. Various subsidiaries under the BlackRock, Inc. umbrella are credited with the holdings, though no single person's interest exceeds 5% of the total outstanding common shares. The reporting person is classified as a parent holding company.